Emergent BioSolutions CEO Joseph C. Papa and CFO Richard S. Lindahl discussed the company’s strong third-quarter earnings call for 2025. Revenue of $231 million exceeded guidance by $21 million, with adjusted EBITDA increasing to $194 million year-to-date. The company’s diversified biodefense and naloxone product portfolio continues to drive growth, with international sales representing 34% of MCM sales. Emergent remains a leader in the biodefense space with ongoing collaborations and transformative investments. Gross margin and profitability improvements highlight the company’s strong performance and strategic growth outlook. The company is focusing on capital deployment, debt repayment, and share repurchases to create shareholder value. Key business catalysts include the Rocket Vaxx collaboration and the growth of NARCAN products in response to the opioid overdose epidemic. International MCM orders are a significant revenue driver with higher gross margins than US sales. The company remains committed to strategic growth and value creation for stakeholders.

Read more at Yahoo Finance: Emergent BioSolutions (EBS) Earnings Transcript